Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Drug survival higher for ixekizumab vs secukinumab in moderate-to-severe plaque psoriasis

11 Jul 2019

More patients with moderate-to-severe plaque psoriasis discontinued treatment with secukinumab despite receiving significantly fewer biologics prior to initiating this drug as compared with those treated with ixekizumab, a recent study has shown.

Secukinumab and ixekizumab were administered to 368 and 62 patients, respectively. The corresponding proportion of bionaive patients was 40.7 percent and 12.9 percent. In addition, patients treated with ixekizumab had been given significantly more biologics in the past.

Of the bionaive patients, 23.5 percent in the secukinumab arm and none in the ixekizumab arm discontinued therapy over 12 months. Drug survival for bionaive and non-naïve patients was higher for ixekizumab than for secukinumab.

During the maximum follow-up of 3 years, drug survival among secukinumab users was lowest for those who have previously received two or more biologics, followed by those who received secukinumab as their second-ever biologic.

In this study, the authors used the DERMBIO registry to examine the drug survival of secukinumab and ixekizumab in a nationwide cohort of patients with moderate-to-severe psoriasis in Denmark. Danish patients receiving treatment with either drug based on standard in-label dosing were included in the analysis. Survival curves were presented using Kaplan-Meier plots.

The study was limited by its relatively small sample size and the short follow-up duration.

“Biologics targeting interleukin 17 are increasingly being used for treatment of moderate-to-severe psoriasis, but data on drug survival for these therapies remain scarce,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.